Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Canopy Growth

Aurora Cannabis

SNDL Inc.

Here's what investors are watching today in the cannabis sector, as a host of the most popular cannabis stocks take off. The post Cannabis Stocks: Why Are ACB, CGC, TLRY, SNDL Stocks Turning Green Today?

Cannabis Stocks: Why Are ACB, CGC, TLRY, SNDL Stocks Turning Green Today?

Marijuana could soon be legal throughout Mexico.

Why Aurora Cannabis, Tilray, and Sundial Growers Stocks Are Smoking Today

TLRY stock continues to be a viable long term bullish thesis. The cannabis sector is still a budding opportunity in its infancy stage.

Tilray Stock Still Needs Time and a Bit of Legislative Help

The second postponement of Tilray's special shareholder meeting to vote on issuing more TLRY stock shows why retail investors aren't nirvana. The post Tilray Stock Is a Buy Here, but a Very Frustrating One appeared first on InvestorPlace.

Tilray Stock Is a Buy Here, but a Very Frustrating One

Investors that added Tilray Inc (NASDAQ:TLRY) to their portfolio one year ago are truly living the high life. Since August 2020, Canadian cannabis company Tilray stock's one-year return has outperformed a number of the world's most popular tech, electric vehicle and clean energy giants: Tesla Inc (NASDAQ:TSLA), Facebook, Inc. (NASDAQ:FB), General Electric Company (NYSE:GE) and Ford Motor Company (NYSE:F).

This Cannabis Company Has A Better 1-Year Return Than Tesla, Facebook, GE And Ford

Tilray Inc. (NASDAQ:TLRY) (TSX:TLRY), a global cannabis-lifestyle and consumer packaged goods company, today sent an open letter to shareholders from Irwin D. Simon, Chairman and Chief Executive Officer.

Read Tilray CEO's Shareholder Letter Mapping Out $4B Revenue Plan

Amplify Seymour Cannabis ETF

Cronos Group

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

Amplify Alternative Harvest ETF

Amplify US Alternative Harvest ETF

AdvisorShares Pure US Cannabis ETF

Global X Cannabis ETF

Trulieve Cannabis Corp.

AXS Cannabis ETF

Cambria Cannabis ETF

AdvisorShares Vice ETF

AdvisorShares Pure Cannabis ETF 

Julian Lin has a new cannabis focused marketplace service, Cannabis Growth Portfolio. We discuss his thoughts on EBITDA, ETFs using total return swaps to own US MSOs, rebalancing away from Canadian operators.

Julian Lin's Highest Conviction Idea (Ever)? Cannabis. (Podcast Transcript)

TLRY stock shouldn't interest investors along with the broader cannabis sector. Too much hope, too little results.

Tilray Stock Looks Worse and Worse, and M&A Isn't Helping

While TLRY stock could benefit from full cannabis legalization in the U.S., that outcome is far from guaranteed to occur. The post Tilray Has a Lot of Potential if the U.S. Legalizes Cannabis appeared first on InvestorPlace.

Tilray Has a Lot of Potential if the U.S. Legalizes Cannabis

The Canadian-based cannabis producer is just the latest company to announce a deal that could set it up for some promising growth prospects south of the border.

Tilray Has Found a Partner for Its Expansion Into the U.S. Pot Market

Rhinomed (OTC:RHNMF) shares closed up 25.36% at $0.26 with an estimated market cap of $66,497,992. Leviathan Natural Prods (OTC:LVCNF) shares closed up 24.29% at $0.5 with an estimated market cap of $42,498,916.

Bullish Tuesday For Marijuana Stocks - Sundial, Aurora, Tilray & Cronos Among Top Gainers

MedMen Enterprises Inc.

Tilray makes its first investment in a US cannabis operator. MedMen was formerly the face of the US cannabis sector, before the stock imploded 95%.

Tilray Buys Into MedMen: What This Means For U.S. Cannabis Stocks

Tilray (NASDAQ:TLRY) shares experienced unusual options activity on Friday. The stock price moved up to $12.76 following the option alert.

Unusual Tilray's Options Spotted

Greenlane Holdings

Akerna Corp

Village Farms International

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.

Six Cannabis Stocks With Breaking News This Week

Hollister Biosciences (OTC: HSTRF) shares closed up 14.84% at $0.21 with an estimated market cap of $55,967,008. Rhinomed (OTC: RHNMF) shares closed up 9.13% at $0.25 with an estimated market cap of $63,706,092.

Buy The Dip! Tilray, Sundial, Aurora Are Down - Looking Into Top Marijuana Stock Movers For Today

What happens if marijuana isn't the only drug that gets legalized?

Why Aurora Cannabis, Tilray, and Sundial Growers Stocks Tumbled Today

Cannabis giant Tilray, Inc. (NASDAQ:TLRY)(TSX:TLRY) convened and then adjourned its special shareholders' meeting on Thursday, postponing it until Sept. 10, 2021. Stockholders had intended to vote on two shareholder proposals: (1) a proposal to increase the authorized number of shares of common stock ("Authorized Shares Proposal"); and (2) a number of governance enhancements to increase stockholder rights (the "Governance Proposals").

Tilray Adjourns Special Meeting Of Stockholders Until Sept. 10

NEW YORK & LEAMINGTON, Ontario--(BUSINESS WIRE)--Tilray, Inc. (“Tilray” or the “Company”) (NASDAQ | TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today convened and then adjourned the Special Meeting of Stockholders intended to approve two shareholder proposals: (1) a proposal to increase the authorized number of shares of common stock (“Authorized Shares Proposal”); and (2) a number of governance enhancements to increase stockholder rights (the “Governanc

Tilray Announces Adjournment of Special Meeting of Stockholders to September 10, 2021

The marijuana giant has its sights set on the potentially massive U.S. cannabis market.

Why Tilray Stock Rose Today

On Wednesday, Tilray Inc. (NASDAQ:TLRY) shares edged 3.4% higher after BofA analysts heaped praise on its latest investment in MedMen Enterprises. The company said it purchased the majority of outstanding convertible notes of MedMen enterprises and BofA sees the investment as a positive for the company's targeted US expansion.

Bank of America sees positives in Tilray's MedMen investment: should you invest in TLRY now?

Tilray Inc (NASDAQ:TLRY) gapped up over 5% higher on Wednesday before dropping down to fill the area and bouncing. After the markets closed on Tuesday, the cannabis giant announced it had acquired a majority stake in amended MedMen Enterprises Inc (OTC:MMNFF) convertible notes for about $165.8 million.

Why Tilray Bears Could Go Up In Smoke If History Repeats

Tilray (TLRY) stock price predictions are of acute interest to investors right now. The stock is primed for gains with its newest purchase.

Tilray (TLRY) Stock Price Predictions: How High Can the MedMen Deal Take TLRY Stock?

Shares of Tilray Inc. rallied Wednesday, on the heels of mostly positive analyst comments on the Canadian cannabis company's announcement to buy a 21% stake in MedMen Enterprises Inc. through the purchase of notes and warrants, to increase its U.S. presence.

The Ratings Game: Analysts upbeat on Tilray's U.S. prospects after MedMen deal

Cannabis name Tilray Inc (NASDAQ:TLRY) is making headlines this morning, after it announced a deal to purchase $165.8 million in convertible debt from U.S. rival MedMen Enterprises.

Tilray Eyes Expansion Into U.S. Weed Market with New Deal

Tilray (TLRY) and MedMen (MMNFF) are in the news Wednesday following the revelation that the former acquired a major stake in the latter. The post TLRY, MMNFF: 9 Things to Know About the Hot Tilray-MedMen Deal appeared first on InvestorPlace.

News for Tilray Brands Stock (TLRY)